The Federal Trade Commission is scheduled to vote today on whether or not to reverse course on prior statements that opposed mandatory PBM transparency and disclosure requirements. The vote, if successful, will effectively remove a major line of defense for PBMs that promote one-sided business relationships, stifle competition and reduce patient choice. NCPA’s General Counsel, Matt Seiler, submitted oral comments to the commissioners encouraging them to vote yes on the matter.